Prostate Cancer Clinical Trials in New York

Showing 321-340 of 453 trials

EXTEND Exercise Trial

NCT02256111

This study will examine the effect of supervised exercise training on cardiopulmonary function in men receiving the combination of enzalutamide (ENZ) and androgen deprivation therapy (ADT) for treatment of non-metastatic, hormone-naïve prostate cancer. No study to date has examined the efficacy, tolerability, and safety of exercise training to prevent and/or mitigate common adverse toxicities in men receiving combination androgen suppression therapy for hormone-naïve prostate cancer.

Non-metastatic, Hormone naïve Prostate Cancer

Duke University26 participantsStarted May 2015

New York, New York, United States • Durham, North Carolina, United States

COMPLETEDPhase 2< 1 mile

Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

NCT03081481

The purpose of this study is to determine a safe, effective, and tolerable dose of PRX302 for the treatment of low to intermediate risk prostate cancer.

Prostate Cancer

Sophiris Bio Corp38 participantsStarted Jun 2017

Ocala, Florida, United States • Baltimore, Maryland, United States • New York, New York, United States +5 more locations

UNKNOWNNA< 1 mile

A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)

NCT00772317

For the treatment of locally recurrent prostate cancer following failed external beam radiation therapy (EBRT)

Recurrent Prostate Cancer

SonaCare Medical117 participantsStarted Jul 2008

Los Angeles, California, United States • Los Angeles, California, United States • Washington D.C., District of Columbia, United States +13 more locations

EXTEND Exercise Trial

Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial)

Prostate Cancer Trials in Other Cities

Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

ClariCore™ Biopsy System in Patients Undergoing Radical Retropubic Prostatectomy

ClariCore System Used in Transrectal Ultrasound Guided Prostate Biopsy for Real-Time Tissue Evaluation

Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T

[18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer

Optical Tomography in Prostate Cancer

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer

Comparative Effectiveness Analysis of Surgery and Radiation (CEASAR) for Localized Prostate Cancer

Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma

CHESS: Human and Computer Mentors for Prostate Cancer Patients

Vidaza to Restore Hormone Thx Prostate

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Other Conditions in New York